Bayer Healthcare Company Profile

✉ Email this page to a colleague

BAYER HEALTHCARE has twenty-nine approved drugs.

There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.

There are four hundred and twenty-nine patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and fifty supplementary protection certificates in seventeen countries.

International Patents:	429
US Patents:	28
Tradenames:	24
Ingredients:	14
NDAs:	29
Patent Litigation for Bayer Healthcare:	See patent lawsuits for Bayer Healthcare

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	9,782,414	⤷ Sign Up				⤷ Sign Up
Bayer Healthcare Llc	MYCELEX-7 COMBINATION PACK	clotrimazole	CREAM, TABLET;TOPICAL, VAGINAL	020389-002	Jun 23, 1994		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Bayer Healthcare Llc	GYNE-LOTRIMIN COMBINATION PACK	clotrimazole	CREAM, TABLET;TOPICAL, VAGINAL	020289-002	Apr 26, 1993		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Bayer Healthcare Llc	CHILDREN'S CLARITIN	loratadine	TABLET, CHEWABLE;ORAL	021891-001	Aug 23, 2006		OTC	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002	4,659,716*PED	⤷ Sign Up
Bayer Healthcare Llc	CLARITIN	loratadine	SYRUP;ORAL	020641-002	Nov 27, 2002	6,132,758	⤷ Sign Up
Bayer Healthcare Llc	CLARITIN	loratadine	SYRUP;ORAL	020641-002	Nov 27, 2002	4,863,931*PED	⤷ Sign Up
Bayer Healthcare	ALIQOPA	copanlisib dihydrochloride	POWDER;INTRAVENOUS	209936-001	Sep 14, 2017	7,511,041	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3106463	2020C/507	Belgium	⤷ Sign Up	PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923
2493858	CR 2020 00020	Denmark	⤷ Sign Up	PRODUCT NAME: DAROLUTAMID EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER EN FARMACEUTISK ACCEPTABELT ESTER DERAF; REG. NO/DATE: EU/1/20/1432/001 20200330
2493858	2020018	Norway	⤷ Sign Up	PRODUCT NAME: DAROLUTAMID, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT ELLER ESTER DERAV; REG. NO/DATE: EU/1/20/1432/ 20200401
3106463	LUC00150	Luxembourg	⤷ Sign Up	PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.